Methods of treating multiple myeloma and myeloma-induced...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/17 (2006.01) A61K 39/395 (2006.01) C07K 14/705 (2006.01) C07K 16/28 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2343579

Antagonists of alpha4 integrin/alpha4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

La présente invention concerne des antagonistes de l'adhésion intégrine alpha4/ligands de l'intégrine alpha4 qui inhibent les effets biologiques d'une telle adhésion, ainsi qu'une description des méthodes correspondantes. Ces antagonistes permettent d'empêcher la destruction osseuse associée au myélome multiple. On inhibe ainsi la migration des cellules myélomateuses vers la moelle osseuse et la libération intégrine-dépendante, par lesdites cellules, de facteurs de résorption osseuse qui conduisent à la destruction osseuse chez les patients atteints de myélome multiple.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods of treating multiple myeloma and myeloma-induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating multiple myeloma and myeloma-induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating multiple myeloma and myeloma-induced... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1599560

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.